GlassScriptPhysician profile
Ladan Ilkhani
NPI 1023315918
$11,867.82
in general payments reported to CMS, 2019-2025
32 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,269 · 2020: $2,066 · 2021: $3,290 · 2022: $2,553 · 2023: $1,277 · 2024: $125 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,394.50 | 2021-2022 | |
| Novo Nordisk INC | $2,038.85 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $1,608.03 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $826.89 | 2019-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $783.33 | 2019-2023 | Fasenra, Breztri, Farxiga |
| Lilly USA, LLC | $541.16 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.07 | 2019-2023 | Jardiance |
| Pfizer INC. | $465.71 | 2019-2023 | |
| Allergan, INC. | $415.66 | 2019-2020 | |
| Glaxosmithkline, LLC. | $290.64 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $289.96 | 2019-2023 | Steglatro, Belsomra |
| Janssen Pharmaceuticals, INC | $221.33 | 2019-2023 | Xarelto |
| Abbott Laboratories | $179.07 | 2022-2023 | Freestyle Libre 3 |
| Medtronic USA, INC. | $147.74 | 2019 | |
| Janssen Biotech, INC. | $147.14 | 2025 | Tremfya, Simponi Aria |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $140.21 | 2019-2023 | Eliquis |
| Sk Life Science, INC. | $125.00 | 2024 | Xcopri |
| Astellas Pharma US INC | $123.39 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $111.44 | 2020-2023 | Austedo |
| Amarin Pharma, INC. | $101.28 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $85.90 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $75.46 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $55.68 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $54.56 | 2020-2021 | |
| Amgen INC. | $40.06 | 2019-2020 | |
| Daiichi Sankyo INC. | $39.89 | 2022 | |
| Avanir Pharmaceuticals, INC. | $24.46 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.91 | 2022 | |
| Genentech USA, INC. | $14.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.72 | 2023 | |
| Sanofi Pasteur INC. | $13.31 | 2019 | |
| Digital Diagnostics INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ladan Ilkhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.